Bioreliance
Bioreliance, a prominent name in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1997, the company has established itself as a leader in providing comprehensive biomanufacturing solutions, including cell line development, viral safety testing, and bioprocessing services. Bioreliance is renowned for its innovative approach to quality control and regulatory compliance, ensuring that its clients meet stringent industry standards. With a strong focus on customisation and client collaboration, the company has achieved significant milestones, including numerous successful partnerships with major pharmaceutical firms. As a trusted partner in the biopharmaceutical sector, Bioreliance continues to enhance its market position through cutting-edge technologies and a commitment to excellence in service delivery.
DitchCarbon Score
How does Bioreliance's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Education Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bioreliance's score of 20 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bioreliance's reported carbon emissions
Bioreliance, headquartered in the US, has reported significant carbon emissions data for the years 2016 to 2019. In 2016, the company emitted approximately 378,000,000 kg CO2e from Scope 1, 404,000,000 kg CO2e from Scope 2, and 426,000,000 kg CO2e from Scope 3 emissions. The following year, 2017, saw a slight increase in Scope 1 emissions to about 384,000,000 kg CO2e, while Scope 2 emissions decreased to approximately 297,000,000 kg CO2e, and Scope 3 emissions reduced to about 353,000,000 kg CO2e. In 2018, Bioreliance's emissions continued to show variability, with Scope 1 emissions at approximately 353,000,000 kg CO2e, Scope 2 at about 313,000,000 kg CO2e, and Scope 3 at around 380,000,000 kg CO2e. By 2019, Scope 1 emissions were approximately 359,000,000 kg CO2e, Scope 2 emissions remained similar at about 306,000,000 kg CO2e, and Scope 3 emissions were approximately 373,000,000 kg CO2e. Despite these figures, Bioreliance has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or any other climate pledges. The company’s emissions data reflects a commitment to transparency, but further details on their climate commitments or reduction strategies are not available.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|
| Scope 1 | 378,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 404,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 426,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bioreliance is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
